Caitrin W McDonough, Ph.D., M.S.
Assistant Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6435
Business Email:
caitrinmcdonough@ufl.edu
About Caitrin W McDonough
Dr. McDonough received a B.S. in Biochemistry (with a minor in chemistry) from the University of Iowa and then earned a Ph.D in Molecular Medicine and Translational Science from Wake Forest University School of Medicine. After completing graduate studies, she completed a Post-Doctoral Fellowship in Cardiovascular Pharmacogenomics under the direction of Dr. Julie Johnson.
Dr. McDonough is an investigator in the Center for Pharmacogenomics. Her research focuses on identifying and predicting patients at high risk for cardiovascular disease. She uses multiple methods (regression modeling and machine learning) to integrate data from multiple sources (e.g. electronic health records, insurance claims, ‘omics) to identify factors or signatures that are associated with adverse cardiovascular outcomes.
Teaching Profile
Courses Taught
2018,2020-2023,2023-2024
PHA6427 Pharmacogenetics of Drug Metabolism
2020-2025
PHA6613 Clinical Applications Precision Medicine: Precision Health
2016,2018-2020,2020-2024,2022-2024,2024
PHA6449 Pharmacogenomic and Genomic Data Analysis
2018-2019,2021-2024
PHA5012 App Personalized Med
2016-2019
PHA5132 Prin Drug Ther Indiv
2016-2018,2024
PHA5878C Pt Care 3: Cv and Pulm
2012-2016
PHA5113 Personalized Medicine
2014-2015
PHA5933 Select Top Pharmacy
2011
PHA5113C Thera Mon/Pharmacogen
2022,2024
PHA7980 Research for Doctoral Dissertation
2022
PHA6910 Supervised Research
2022-2025
PHA7979 Advanced Research
2022-2025
PHA5040 Pharmacogenomic Literature Assessment
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-6393-7288
Areas of Interest
- Cardiovascular Disease
- Electronic medical records
- Hypertension
- Pharmacoepidemiology
- Pharmacogenetics
Publications
Academic Articles
2024
Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
American journal of hypertension.
37(1):60-68
[DOI] 10.1093/ajh/hpad084.
[PMID] 37712350.
2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score.
Journal of the American College of Cardiology.
83(15):1370-1381
[DOI] 10.1016/j.jacc.2024.02.015.
[PMID] 38599713.
2024
Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks.
BMC cardiovascular disorders.
24(1)
[DOI] 10.1186/s12872-024-04161-x.
[PMID] 39289597.
2023
Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2023.04.28.23289293.
[PMID] 37205447.
2023
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
113(3):615-623
[DOI] 10.1002/cpt.2776.
[PMID] 36306392.
2023
Radiomics-Derived Brain Age Predicts Functional Outcome After Acute Ischemic Stroke.
Neurology.
100(8):e822-e833
[DOI] 10.1212/WNL.0000000000201596.
[PMID] 36443016.
2023
The relevance of rich club regions for functional outcome post-stroke is enhanced in women.
Human brain mapping.
44(4):1579-1592
[DOI] 10.1002/hbm.26159.
[PMID] 36440953.
2023
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program.
Frontiers in genetics.
14
[DOI] 10.3389/fgene.2023.1278215.
[PMID] 38162683.
2022
Association of Stroke Lesion Pattern and White Matter Hyperintensity Burden With Stroke Severity and Outcome.
Neurology.
99(13):e1364-e1379
[DOI] 10.1212/WNL.0000000000200926.
[PMID] 35803717.
2022
Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke.
Neurology.
99(16):e1738-e1754
[DOI] 10.1212/WNL.0000000000201006.
[PMID] 36240095.
2022
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association.
11(4)
[DOI] 10.1161/JAHA.121.024159.
[PMID] 35156424.
2022
Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.
Frontiers in genetics.
13
[DOI] 10.3389/fgene.2022.1085994.
[PMID] 36712853.
2022
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.
Genes.
13(7)
[DOI] 10.3390/genes13071260.
[PMID] 35886043.
2022
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers.
The pharmacogenomics journal.
22(1):62-68
[DOI] 10.1038/s41397-021-00257-1.
[PMID] 34642472.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics.
112(1):146-155
[DOI] 10.1002/cpt.2612.
[PMID] 35429163.
2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.
Metabolites.
12(9)
[DOI] 10.3390/metabo12090783.
[PMID] 36144188.
2022
Sex-specific lesion pattern of functional outcomes after stroke.
Brain communications.
4(2)
[DOI] 10.1093/braincomms/fcac020.
[PMID] 35282166.
2021
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
Clinical pharmacology and therapeutics.
110(3):723-732
[DOI] 10.1002/cpt.2355.
[PMID] 34231218.
2021
Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects.
Frontiers in genetics.
12
[DOI] 10.3389/fgene.2021.701405.
[PMID] 34408773.
2021
Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics
JACCP: Journal of the American College of Clinical Pharmacy.
4(3):343-352
[DOI] 10.1002/jac5.1335.
2021
Excessive White Matter Hyperintensity Increases Susceptibility to Poor Functional Outcomes After Acute Ischemic Stroke.
Frontiers in neurology.
12
[DOI] 10.3389/fneur.2021.700616.
[PMID] 34566844.
2021
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
European Heart Journal.
42(18):1742-1756
[DOI] 10.1093/eurheartj/ehab107.
[PMID] 33748830.
2021
Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw.
Clinical pharmacology and therapeutics.
110(6):1558-1569
[DOI] 10.1002/cpt.2397.
[PMID] 34390503.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites.
11(9)
[DOI] 10.3390/metabo11090645.
[PMID] 34564461.
2021
MRI Radiomic Signature of White Matter Hyperintensities Is Associated With Clinical Phenotypes.
Frontiers in neuroscience.
15
[DOI] 10.3389/fnins.2021.691244.
[PMID] 34321995.
2021
Outcome after acute ischemic stroke is linked to sex-specific lesion patterns.
Nature communications.
12(1)
[DOI] 10.1038/s41467-021-23492-3.
[PMID] 34078897.
2021
Pharmacogenomics in Cardiovascular Diseases.
Current protocols.
1(7)
[DOI] 10.1002/cpz1.189.
[PMID] 34232575.
2021
SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
36(2):347-356
[DOI] 10.1002/jbmr.4185.
[PMID] 32967053.
2020
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.
American journal of hypertension.
33(4):316-324
[DOI] 10.1093/ajh/hpz196.
[PMID] 31853537.
2020
Correction: Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network’s Common Measures Working Group.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(10)
[DOI] 10.1038/s41436-020-0910-6.
[PMID] 32719392.
2020
Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison
JMIR Medical Informatics.
8(2)
[DOI] 10.2196/14777.
[PMID] 32130152.
2020
Optimizing identification of resistant hypertension: Computable phenotype development and validation
Pharmacoepidemiology and Drug Safety.
29(11):1393-1401
[DOI] 10.1002/pds.5095.
[PMID] 32844549.
2020
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
American journal of hypertension.
33(2)
[DOI] 10.1093/ajh/hpz168.
[PMID] 31891170.
2020
Translational Informatics Connects Real-World Information to Knowledge in an Increasingly Data-Driven World.
Clinical pharmacology and therapeutics.
107(4):738-741
[DOI] 10.1002/cpt.1719.
[PMID] 31837229.
2019
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
Journal of clinical hypertension (Greenwich, Conn.).
21(1):91-101
[DOI] 10.1111/jch.13429.
[PMID] 30427124.
2019
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-53345-5.
[PMID] 31754133.
2019
Genome-wide association analysis of common genetic variants of resistant hypertension.
The pharmacogenomics journal.
19(3):295-304
[DOI] 10.1038/s41397-018-0049-x.
[PMID] 30237584.
2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
Journal of the American Heart Association.
8(16)
[DOI] 10.1161/JAHA.119.013115.
[PMID] 31423876.
2019
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clinical and translational science.
12(5):497-504
[DOI] 10.1111/cts.12643.
[PMID] 31033190.
2019
IGNITE network: Response of patients to genomic medicine interventions.
Molecular genetics & genomic medicine.
7(5)
[DOI] 10.1002/mgg3.636.
[PMID] 30895746.
2019
Pharmacogenomics of osteonecrosis of the jaw.
Bone.
124:75-82
[DOI] 10.1016/j.bone.2019.04.010.
[PMID] 31022475.
2019
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
American journal of hypertension.
32(7):668-675
[DOI] 10.1093/ajh/hpz022.
[PMID] 30753254.
2018
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC medical genomics.
11(1)
[DOI] 10.1186/s12920-018-0370-x.
[PMID] 29925376.
2018
Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network’s Common Measures Working Group.
Genetics in medicine : official journal of the American College of Medical Genetics.
20(6):655-663
[DOI] 10.1038/gim.2017.144.
[PMID] 28914267.
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circulation. Genomic and precision medicine.
11(4)
[DOI] 10.1161/CIRCGEN.117.001854.
[PMID] 29650764.
2018
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
Journal of the American Heart Association.
7(6)
[DOI] 10.1161/JAHA.117.007339.
[PMID] 29523524.
2018
Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.
The pharmacogenomics journal.
18(1):106-112
[DOI] 10.1038/tpj.2016.67.
[PMID] 27670767.
2018
Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network.
Preventing chronic disease.
15
[DOI] 10.5888/pcd15.170332.
[PMID] 29494332.
2018
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
Clinical and translational science.
11(2):175-181
[DOI] 10.1111/cts.12533.
[PMID] 29351371.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of clinical hypertension (Greenwich, Conn.).
19(12):1301-1308
[DOI] 10.1111/jch.13094.
[PMID] 28940643.
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Journal of the American Heart Association.
6(11)
[DOI] 10.1161/JAHA.117.006522.
[PMID] 29097388.
2017
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
69(1):51-59
[PMID] 27802415.
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
Circulation. Cardiovascular genetics.
10(1)
[DOI] 10.1161/CIRCGENETICS.116.001404.
[PMID] 28115488.
2017
Genome-wide study of resistant hypertension identified from electronic health records.
PloS one.
12(2)
[DOI] 10.1371/journal.pone.0171745.
[PMID] 28222112.
2017
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
Stroke.
48(5):1337-1343
[DOI] 10.1161/STROKEAHA.116.015936.
[PMID] 28351962.
2017
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-16343-z.
[PMID] 29167564.
2016
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension (Dallas, Tex. : 1979).
68(3):621-9
[DOI] 10.1161/HYPERTENSIONAHA.116.07328.
[PMID] 27381900.
2016
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Journal of neurosurgery.
124(6):1746-51
[DOI] 10.3171/2015.6.JNS15795.
[PMID] 26587656.
2016
Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course.
American journal of pharmaceutical education.
80(7)
[PMID] 27756930.
2016
Genetic Moderators of the Impact of Physical Activity on Depressive Symptoms.
The Journal of frailty & aging.
5(1):6-14
[DOI] 10.14283/jfa.2016.76.
[PMID] 26980363.
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Clinical and translational science.
9(2):114-22
[DOI] 10.1111/cts.12389.
[PMID] 26946962.
2016
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics : Official journal of the Metabolomic Society.
12(8)
[DOI] 10.1007/s11306-016-1076-8.
[PMID] 28217400.
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Hypertension (Dallas, Tex. : 1979).
67(3):556-63
[DOI] 10.1161/HYPERTENSIONAHA.115.06345.
[PMID] 26729753.
2015
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Journal of the American Heart Association.
4(6)
[DOI] 10.1161/JAHA.114.001652.
[PMID] 26019129.
2015
Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children.
Journal of clinical pharmacology.
55(1):50-5
[DOI] 10.1002/jcph.371.
[PMID] 25079374.
2015
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Journal of hypertension.
33(11):2278-85
[DOI] 10.1097/HJH.0000000000000714.
[PMID] 26425837.
2015
The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.
Pharmacogenetics and genomics.
25(5):239-45
[DOI] 10.1097/FPC.0000000000000129.
[PMID] 25738370.
2014
A Pharmacogenomic Genome-Wide Association Study for Adverse Cardiovascular Outcomes in the International Verapamil Sr-Trandolapril Study (Invest)
Clinical Pharmacology & Therapeutics.
95(1)
2014
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations.
Human molecular genetics.
23(9):2498-510
[DOI] 10.1093/hmg/ddt626.
[PMID] 24345515.
2014
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.
American journal of human genetics.
94(3):349-60
[DOI] 10.1016/j.ajhg.2013.12.016.
[PMID] 24560520.
2014
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Journal of internal medicine.
276(5):486-97
[DOI] 10.1111/joim.12215.
[PMID] 24612202.
2014
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
Journal of the American Heart Association.
3(6)
[DOI] 10.1161/JAHA.114.001398.
[PMID] 25385345.
2014
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy.
34(2):123-30
[DOI] 10.1002/phar.1355.
[PMID] 24122840.
2013
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
The pharmacogenomics journal.
13(5):430-6
[DOI] 10.1038/tpj.2012.34.
[PMID] 22907731.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076984.
[PMID] 24116192.
2013
Fasting Glucose Loci Associated With Glucose Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
Clinical Pharmacology & Therapeutics.
93
2013
Fasting Glucose Loci Associated With Glucose Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
Clinical Pharmacology & Therapeutics.
93
2013
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
62(2):391-7
[DOI] 10.1161/HYPERTENSIONAHA.111.00436.
[PMID] 23753411.
2013
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Pharmacogenetics and genomics.
23(12):697-705
[DOI] 10.1097/FPC.0000000000000012.
[PMID] 24128935.
2013
Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort.
Journal of translational medicine.
11
[DOI] 10.1186/1479-5876-11-12.
[PMID] 23302499.
2013
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
Human molecular genetics.
22(8):1663-78
[DOI] 10.1093/hmg/dds555.
[PMID] 23303523.
2013
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Hypertension (Dallas, Tex. : 1979).
62(1):48-54
[DOI] 10.1161/HYPERTENSIONAHA.111.00823.
[PMID] 23690342.
2012
A genome-wide association search for type 2 diabetes genes in African Americans.
PloS one.
7(1)
[DOI] 10.1371/journal.pone.0029202.
[PMID] 22238593.
2012
Alpha Adducin-1 (Add1)Singlenucleotide Polymorphism (Snp) Associated With New Onset Diabetes Risk With Hydrochlorothiazide (Hctz) Therapy in the International Verapamil Sr Trandolapril Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics.
91:S59-S60
2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circulation. Cardiovascular genetics.
5(6):686-91
[DOI] 10.1161/CIRCGENETICS.112.964080.
[PMID] 23087401.
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
American journal of human genetics.
91(5):823-38
[DOI] 10.1016/j.ajhg.2012.08.032.
[PMID] 23063622.
2012
Non-Synonymous Snps in Sele, Selp, and Siglec12 Associate With Cardiovascular (Cv) Outcomes in the International Verapamil Sr-Trandol-April Study Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91:S20-S21
2011
A genome-wide association study for diabetic nephropathy genes in African Americans.
Kidney international.
79(5):563-72
[DOI] 10.1038/ki.2010.467.
[PMID] 21150874.
2011
Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
PLoS genetics.
7(6)
[DOI] 10.1371/journal.pgen.1002150.
[PMID] 21698141.
2011
Genome-wide association scan for survival on dialysis in African-Americans with type 2 diabetes.
American journal of nephrology.
33(6):502-9
[DOI] 10.1159/000327985.
[PMID] 21546767.
2009
A comparative study of Drosophila and human A-type lamins.
PloS one.
4(10)
[DOI] 10.1371/journal.pone.0007564.
[PMID] 19855837.
2009
Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping.
Human genetics.
126(6):805-17
[DOI] 10.1007/s00439-009-0732-8.
[PMID] 19690890.
2009
The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans.
Human genetics.
126(2):265-75
[DOI] 10.1007/s00439-009-0667-0.
[PMID] 19373489.
2007
A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association.
22(4):1131-5
[PMID] 17205963.
Grants
Jul 2024
ACTIVE
Development of Integrated Precision Medicine Models in Adults with Cardiovascular Disease
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Jul 2024
ACTIVE
Cardiovascular Adverse Events Related to Aromatase Inhibitors in Breast Cancer
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Mar 2024
– Aug 2024
Cardiovascular Adverse Events Related to Aromatase Inhibitors in Female Breast Cancer
Role: Consultant
Funding: ARIZONA STATE UNIVERSITY
via NATL INST OF HLTH
Sep 2023
ACTIVE
Hypertension Prediction and Identification in All of Us
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Sep 2021
ACTIVE
Preemptive pharmacogenetic testing in medically underserved populations
Role: Co-Investigator
Funding: NATL INST OF HLTH NHGRI
Jul 2021
– Jun 2024
Using Artificial Intelligence to Identify Patients Most Likely to Benefit from Preemptive Pharmacogenetic Testing
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jun 2021
– Aug 2021
Replication of GenHAT GWAS signals in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and Genetic Epidemiology of Responses to Antihypertensives (GERA)
Role: Principal Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM
via NATL INST OF HLTH
Jul 2020
ACTIVE
Precision antiplatelet therapy after percutaneous coronary intervention
Role: Other
Funding: NATL INST OF HLTH NHLBI
Jun 2020
ACTIVE
1Florida Alzheimers Disease Research Center
Role: Project Manager
Funding: NATL INST OF HLTH NIA
Apr 2020
– Mar 2021
Use of Real-World Evidence to Characterize Patients with Uncontrolled Hypertension
Role: Other
Funding: YALE CENTER FOR OUTCOMES RESEARCH & EVAL
via MEDICAL DEVICE INNOVATION CONSORTIUM
Jun 2018
– Jun 2022
INTEGRATIVE DATA APPROCACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTION
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Apr 2017
– Mar 2018
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Apr 2016
– Mar 2017
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE ,HEALTH ,
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Education
M.S.
2019
·
University of Florida
Ph.D.
2010
·
Wake Forest University School of Medicine
Contact Details
Phones:
- Business:
- (352) 273-6435
Emails:
- Business:
- caitrinmcdonough@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610